NICM
CRSP icon

Neo Ivy Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Neo Ivy Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,725
Closed -$82.1K – 391
2026
Q1 		$82.1K Sell
1,725
-77,001
-98% -$4.06M 0.02% 287
2025
Q4 		$4.13M Buy
+78,726
New +$4.71M 0.65% 50

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Neo Ivy Capital Management's CRSP Position: Q2 2026 in Review

Neo Ivy Capital Management sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 1,725 shares — an estimated $82.1K sold.

Neo Ivy Capital Management first reported a position in CRSP in Q4 2025 and held it in 2 quarters. The position peaked at $4.13M in Q4 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Neo Ivy Capital Management reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Neo Ivy Capital Management sold 1,725 CRISPR Therapeutics shares in Q2 2026, an estimated $82.1K.
  • Neo Ivy Capital Management first reported a position in CRISPR Therapeutics in Q4 2025 and held it in 2 quarters.
  • Neo Ivy Capital Management's CRISPR Therapeutics position peaked at $4.13M in Q4 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.